Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 578453, 6 pages
http://dx.doi.org/10.1155/2015/578453
Review Article

The Potential Role of NFAT5 and Osmolarity in Peritoneal Injury

1Division of Nephrology, University Hospital Zurich, 8091 Zurich, Switzerland
2Institute of Physiology and Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, 8057 Zurich, Switzerland
3Division of Nephrology, Department of Internal Medicine, Robert-Bosch-Hospital, 70376 Stuttgart, Germany

Received 9 June 2015; Accepted 12 July 2015

Academic Editor: Donald Fraser

Copyright © 2015 Harald Seeger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. M. El Nahas and A. K. Bello, “Chronic kidney disease: the global challenge,” The Lancet, vol. 365, no. 9456, pp. 331–340, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Chaudhary, H. Sangha, and R. Khanna, “Peritoneal dialysis first: rationale,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 2, pp. 447–456, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. F. X. Liu, X. Gao, G. Inglese, P. Chuengsaman, R. Pecoits-Filho, and A. Yu, “A global overview of the impact of peritoneal dialysis first or favored policies: an opinion,” Peritoneal Dialysis International, 2014. View at Publisher · View at Google Scholar
  4. T. W. Meyer and T. H. Hostetter, “Uremia,” The New England Journal of Medicine, vol. 357, no. 13, pp. 1316–1325, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. S. J. Davies, L. Phillips, A. M. Griffiths, L. H. Russell, P. F. Naish, and G. I. Russell, “What really happens to people on long-term peritoneal dialysis?” Kidney International, vol. 54, no. 6, pp. 2207–2217, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. S. J. Davies, J. Bryan, L. Phillips, and G. I. Russell, “Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis,” Nephrology Dialysis Transplantation, vol. 11, no. 3, pp. 498–506, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. D. N. Churchill, K. E. Thorpe, K. D. Nolph, P. R. Keshaviah, D. G. Oreopoulos, and D. Pagé, “Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients,” Journal of the American Society of Nephrology, vol. 9, no. 7, pp. 1285–1292, 1998. View at Google Scholar · View at Scopus
  8. K. Honda, C. Hamada, M. Nakayama et al., “Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 3, pp. 720–728, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. J. D. Williams, K. J. Craig, N. Topley et al., “Morphologic changes in the peritoneal membrane of patients with renal disease,” Journal of the American Society of Nephrology, vol. 13, no. 2, pp. 470–479, 2002. View at Google Scholar · View at Scopus
  10. Y. Cho, D. W. Johnson, S. V. Badve, J. C. Craig, G. F. M. Strippoli, and K. J. Wiggins, “The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients,” Kidney International, vol. 84, no. 5, pp. 969–979, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Cho, D. W. Johnson, S. Badve, J. C. Craig, G. F. K. Strippoli, and K. J. Wiggins, “Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials,” Nephrology Dialysis Transplantation, vol. 28, no. 7, pp. 1899–1907, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Witowski, T. O. Bender, J. Wisniewska-Elnur et al., “Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se,” Peritoneal Dialysis International, vol. 23, no. 4, pp. 381–390, 2003. View at Google Scholar · View at Scopus
  13. J. Witowski, T. O. Bender, G. M. Gahl, U. Frei, and A. Jörres, “Glucose degradation products and peritoneal membrane function,” Peritoneal Dialysis International, vol. 21, no. 2, pp. 201–205, 2001. View at Google Scholar · View at Scopus
  14. M. B. Burg, J. D. Ferraris, and N. I. Dmitrieva, “Cellular response to hyperosmotic stresses,” Physiological Reviews, vol. 87, no. 4, pp. 1441–1474, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Neuhofer, “Role of NFAT5 in inflammatory disorders associated with osmotic stress,” Current Genomics, vol. 11, no. 8, pp. 584–590, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Yang, A. D. Hodgkinson, P. J. Oates, H. M. Kwon, B. A. Millward, and A. G. Demaine, “Elevated activity of transcription factor nuclear factor of activated T-cells 5 (NFAT5) and diabetic nephropathy,” Diabetes, vol. 55, no. 5, pp. 1450–1455, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. C. López-Rodríguez, J. Aramburu, L. Jin, A. S. Rakeman, M. Michino, and A. Rao, “Bridging the NFAT and NF-kappaB families: NFAT5 dimerization regulates cytokine gene transcription in response to osmotic stress,” Immunity, vol. 15, no. 1, pp. 47–58, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Shapiro and C. A. Dinarello, “Hyperosmotic stress as a stimulant for proinflammatory cytokine production,” Experimental Cell Research, vol. 231, no. 2, pp. 354–362, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Roth, V. Leroy, H. M. Kwon, P.-Y. Martin, E. Féraille, and U. Hasler, “Osmoprotective transcription factor NFAT5/TonEBP modulates nuclear factor-κB activity,” Molecular Biology of the Cell, vol. 21, no. 19, pp. 3459–3474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Ha and H. B. Lee, “Effect of high glucose on peritoneal mesothelial cell biology,” Peritoneal Dialysis International, vol. 20, supplement 2, pp. S15–S18, 2000. View at Google Scholar · View at Scopus
  21. S. K. Lee, B. S. Kim, W. S. Yang, S. B. Kim, S. K. Park, and J. S. Park, “High glucose induces MCP-1 expression partly via tyrosine kinase-AP-1 pathway in peritoneal mesothelial cells,” Kidney International, vol. 60, no. 1, pp. 55–64, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Matsuo, M. Tamura, N. Kabashima et al., “Prednisolone inhibits hyperosmolarity-induced expression of MCP-1 via NF-κB in peritoneal mesothelial cells,” Kidney International, vol. 69, no. 4, pp. 736–746, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Y. H. Wong, A. O. Phillips, J. Witowski, and N. Topley, “Glucose-mediated induction of TGF-beta 1 and MCP-1 in mesothelial cells in vitro is osmolality and polyol pathway dependent,” Kidney International, vol. 63, no. 4, pp. 1404–1416, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Kitterer, J. Latus, C. Ulmer et al., “Activation of nuclear factor of activated T cells 5 in the peritoneal membrane of uremic patients,” The American Journal of Physiology—Renal Physiology, vol. 308, no. 11, pp. F1247–F1258, 2015. View at Publisher · View at Google Scholar
  25. G. Shaikh, R. Sehgal, S. Sandhu, S. Vaddineni, J. Fogel, and S. Rubinstein, “Changes in osmol gap in chronic kidney disease: an exploratory study,” Renal Failure, vol. 36, no. 2, pp. 198–201, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Dursun, A. Noyan, N. Cengiz et al., “Changes in osmolal gap and osmolality in children with chronic and end-stage renal failure,” Nephron: Physiology, vol. 105, no. 2, pp. p19–p21, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Griveas, A. Gompou, I. Kyritsis et al., “Osmolal gap in hemodialyzed uremic patients,” Artificial Organs, vol. 36, no. 1, pp. 16–20, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Breborowicz, A. Polubinska, and D. G. Oreopoulos, “Changes in volume of peritoneal mesothelial cells exposed to osmotic stress,” Peritoneal Dialysis International, vol. 19, no. 2, pp. 119–123, 1999. View at Google Scholar · View at Scopus
  29. J.-P. Rougier, P. Moullier, R. Piedagnel, and P. M. Ronco, “Hyperosmolality suppresses but TGFβ1 increases MMP9 in human peritoneal mesothelial cells,” Kidney International, vol. 51, no. 1, pp. 337–347, 1997. View at Publisher · View at Google Scholar · View at Scopus
  30. F. N. Miller, K. D. Nolph, I. G. Joshua, D. L. Wiegman, P. D. Harris, and D. B. Andersen, “Hyperosmolality, acetate, and lactate: dilatory factors during peritoneal dialysis,” Kidney International, vol. 20, no. 3, pp. 397–402, 1981. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Zakaria, A. Althani, A. A. Fawzi, and O. M. Fituri, “Hyperosmolality-mediated peritoneal microvascular vasodilation is linked to aquaporin function,” Advances in Peritoneal Dialysis, vol. 30, pp. 63–74, 2014. View at Google Scholar · View at Scopus
  32. E. R. A. Zakaria, A. Althani, A. A. Fawzi, and O. M. Fituri, “Molecular mechanisms of peritoneal dialysis-induced microvascular vasodilation,” Advances in Peritoneal Dialysis, vol. 30, pp. 98–109, 2014. View at Google Scholar · View at Scopus
  33. D. M. Alscher, D. Biegger, T. Mettang, H. van der Kuip, U. Kuhlmann, and P. Fritz, “Apoptosis of mesothelial cells caused by unphysiological characteristics of peritoneal dialysis fluids,” Artificial Organs, vol. 27, no. 11, pp. 1035–1040, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Küper, F.-X. Beck, and W. Neuhofer, “NFAT5 contributes to osmolality-induced MCP-1 expression in mesothelial cells,” Mediators of Inflammation, vol. 2012, Article ID 513015, 12 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. W. Y. Go, X. Liu, M. A. Roti, F. Liu, and S. N. Ho, “NFATS/TonEBP mutant mice define osmotic stress as a critical feature of the lymphoid microenvironment,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 29, pp. 10673–10678, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Kojima, H. Taniguchi, A. Tsuzuki, K. Nakamura, Y. Sakakura, and M. Ito, “Hypertonicity-induced expression of monocyte chemoattractant protein-1 through a novel cis-acting element and MAPK signaling pathways,” Journal of Immunology, vol. 184, no. 9, pp. 5253–5262, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Witowski and A. Jörres, “Peritoneal cell culture: fibroblasts,” Peritoneal Dialysis International, vol. 26, no. 3, pp. 292–299, 2006. View at Google Scholar · View at Scopus
  38. D. Maouyo, J. Y. Kim, S. D. Lee, Y. Wu, S. K. Woo, and H. M. Kwon, “Mouse TonEBP-NFAT5: expression in early development and alternative splicing,” The American Journal of Physiology—Renal Physiology, vol. 282, no. 5, pp. F802–F809, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Jauliac, C. López-Rodriguez, L. M. Shaw, L. F. Brown, A. Rao, and A. Toker, “The role of NFAT transcription factors in integrin-mediated carcinoma invasion,” Nature Cell Biology, vol. 4, no. 7, pp. 540–544, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Trama, Q. Lu, R. G. Hawley, and S. N. Ho, “The NFAT-related protein NFATL1 (TonEBP/NFAT5) is induced upon T cell activation in a calcineurin-dependent manner,” Journal of Immunology, vol. 165, no. 9, pp. 4884–4894, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. H.-J. Yoon, S. You, S.-A. Yoo et al., “NF-AT5 is a critical regulator of inflammatory arthritis,” Arthritis & Rheumatism, vol. 63, no. 7, pp. 1843–1852, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. J. A. Halterman, H. M. Kwon, R. Zargham, P. D. S. Bortz, and B. R. Wamhoff, “Nuclear factor of activated T cells 5 regulates vascular smooth muscle cell phenotypic modulation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 10, pp. 2287–2296, 2011. View at Publisher · View at Google Scholar · View at Scopus